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12 times more likely to be NWH compared to those walking at normal speed (Odds 
Ratio [OR]: 12.4 95% Confidence Interval [CI] 6.0 -25.6; p< 0.001), after controlling for 
age, gender, race, education, body mass index (BMI), income, and comorbidities. 
Further, the contribution of comorbidities in the model was significantly (p< 0.001) 
weakened when WS entered the model. ConClusions: Walking speed was an 
independent predictor of NWH status among community dwelling women and 
may be useful in the work setting to identify those at high risk of health related job 
loss. Further evaluation of the longitudinal predictive capability of WS is needed.
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objeCtives: To develop a questionnaire for completion by patients presenting with 
shoulder instability. Methods: A draft 18 item questionnaire was developed using 
themes identified from interviews with patients (n= 20). The draft questionnaire 
was then tested on further groups of 20 patients attending an outpatient clinic, to 
which they had been referred with instability of the shoulder. Following modifica-
tion resulting from patient feedback, the revised 12 item questionnaire was then 
tested in a prospective study of consecutive patients attending out-patient clinics 
for shoulder instability (n= 98). Patients completed patient-reported and clinical 
assessments pre-intervention (physiotherapy or surgery) and again at 6 months 
following treatment. The questionnaire was evaluated regarding its internal consist-
ency, reproducibility, validity and responsiveness (sensitivity to change). Results: 
The results provide evidence of good measurement properties of the questionnaire: 
Internal consistency - Cronbach’s alpha was 0.91 at the pre-treatment assessment (n 
= 92) and 0.92 at follow-up (n = 64). Reproducibility - In the test-retest sample (n = 
34), the correlation between the total scores for the questionnaire was high (r = 0.97, 
p < 0.0001), coefficient of reliability 5.7. Construct validity - The new questionnaire 
correlated well with the Constant and Rowe clinical scores both before operation 
and at the six-month follow-up. It also agreed significantly with the related parts 
of the SF36, particularly in physical function and pain. Responsiveness – The new 
questionnaire and the Rowe clinical score (but not the Constant) each achieved a 
large standardised effect size (≥ 0.8) that surpassed values obtained on relevant 
SF36 domains. ConClusions: We developed and tested a short patient-reported 
12-item questionnaire (‘score’) which patients have found easy to complete and 
which provides reliable, valid and responsive information as to their perception 
of shoulder instability.
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objeCtives: Much information about the disease experience can only be obtained 
directly from patients. However, biases may be introduced to patient-reported 
research depending on the source of the sample. This analysis seeks to identify 
differences in demographic and disease characteristics between samples of patients 
with rheumatoid arthritis (RA) recruited through an advocacy organization and 
a consumer panel. Methods: Data were collected online from two groups of 
patients through self-administered questionnaires. Patients were recruited through 
the patient advocacy organization CreakyJoints and the Lightspeed Research con-
sumer panel. Patients in both groups were U.S. adults (aged ≥ 18), diagnosed with 
RA, currently treated by a rheumatologist with disease modifying anti-rheumatic 
drugs (DMARDs), and with no history of biologic use but had discussed biolog-
ics with their physician. Results: A total of 243 patients completed the study. Of 
these, 101 were from the advocacy organization and 142 were from the consumer 
panel. Patients from the advocacy organization were younger (mean age, 46 vs. 57) 
and more likely to be female (93% vs. 80%), employed (53% vs. 31%), have a college 
degree (59% vs. 43%), and have commercial insurance (70% vs. 51%) than patients 
from the consumer panel (p< 0.05 for all comparisons). Patients from the advocacy 
organization also began experiencing RA symptoms more recently (mean years 
since symptom development, 10 vs. 15) and were more likely to be diagnosed by a 
rheumatologist (73% vs. 51%), have a caregiver (47% vs. 24%), and be non-adherent 
with medication (61% vs. 42%) than patients from the consumer panel (p< 0.05 for all 
comparisons). ConClusions: Members of patient advocacy organizations and con-
sumer panels can differ demographically and in their disease characteristics. The 
potential impact of these differences on study results should be considered when 
developing a sampling and recruitment plan for patient-centered survey research.
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objeCtives: Identifying those at highest risk of poor outcomes is critical to popu-
lation health management. The purpose of this study was to identify preoperative 
factors and comorbidities that are associated with those at risk of poor patient-
reported physical function recovery one year following total knee arthroplasty 
(TKA). Methods: Primary TKA unilateral procedures from a patient-reported total 
However, further methodological research is needed to achieve standardization 
of procedures.
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objeCtives: The aim of this study was to measure what matters most in WTP for 
a treatment, the patients’ perception of their health status, their ability to pay, or a 
combination of both. Methods: 395 US patients diagnosed with either psoriasis 
(n= 151) or psoriatic arthritis (n= 247) completed a questionnaire as part of a broader 
survey of treatment of psoriasis/psoriatic arthritis in the US. The questionnaire 
included the EQ-5D-5L instrument and accompanying VAS. Patients were addition-
ally asked to indicate by reference to the EQ-5D VAS scale the amount of money 
per month they would be willing to pay for treatments that would improve their 
health status by 10 points, retain their current health and prevent a decline in 
health status by 10 points. Annual household income information was also reported 
by patients. Patients were split into 3 equal groups based on their VAS. Results: 
Household income was a better predictor of WTP for a treatment; those patients 
with an annual income of less than $25000 were willing to pay the least (p< 0,001), 
whereas patients with an annual household income over $75000 would pay most 
(p< 0,001). Patients within the lowest VAS segment were prepared to pay significantly 
more for an improvement in their health status than patients within the other seg-
ments (p< 0,003). No significant differences were noted between groups to either 
retain health status or avoid health decline. For predicting WTP for an improvement 
in health status, a combination of low yearly income (< $25000) and the EQ-5D VAS 
was the best (sig < 0.001); WTP for a 10 VAS point improvement = $142 + (-$39,9*Low 
Income) + (-$0,7*VAS score). ConClusions: Both ability to pay and health status 
are valid predictors of willingness to pay for a treatment. Yet ability to pay is a better 
overall predictor of willingness to pay than HRQoL.
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objeCtives: To evaluate the benefits in functional status and labor productivity 
of tofacitinib in patients with inadequate response to a non-biological DMARD vs 
anti-TNF in Colombia. Methods: The response to treatment was assessed by the 
change from baseline in the Health Assessment Questionnaire-Disability Index 
(HAQ-DI) from baseline and works lost productivity: absenteeism and presentee-
ism (productivity reduction ≥ 50%) due patient’s functional status, as reported by 
Chaparro del Moral R. 2012 and Hazes JM. 2010 who measured absenteeism accord-
ing to functional status regardless of treatment received. Comparison between anti-
TNF and tofacitinib (5mg BID) was done directly to adalimumab (heat-to-heat study) 
and indirectly (Bucher´s indirect comparisons adjusted method) vs other anti-TNF 
available in Colombia (certolizumab, etanercept, golimumab and infliximab) using 
methotrexate as reference therapy. A discrete event model that simulates six cohorts 
of 1,000 patients (each per treatment option) was developed; productivity hours 
lost was projected according to HAQ level (< 0.5; 0.5-0.87; > 0.87), during 52 weeks 
horizon. Variations in HAQ levels (basal and weekly mean chance), absenteeism 
and presenteeism hours were probabilistically generated assuming a normal dis-
tribution. The results obtained with the anti-TNF’s are grouped and weighted given 
their market share as reported in the SISMED by the Health Ministry. Results: 
Improvement in HAQ-DI score at 3, 6, 9 and 12 months from baseline with tofaci-
tinib and anti -TNF were 61.9, 48.7, 65.2 and 53.2%; and, 49.5, 42.7, 57.1 and 47.1%, 
respectively (t-test at 52 weeks, p< 0.001). As result of these reductions, the hours 
of absenteeism/presenteeism losses along the 52-week horizon were obtained, at 
last observation week: 2.72/2.67 and 4.04/7.23 hours with tofacitinib and anti-TNF 
respectively. ConClusions: The superior reduction in HAQ-DI scale at 52 weeks 
obtained with Tofacitinib in patients with inadequate response to a non-biological 
DMARD results in a greater reduction in work lost productivity, presenteeism and 
absenteeism, compared to anti-TNF available in Colombia.
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objeCtives: Early identification of declining health in working adults with osteo-
arthritis (OA) may allow targeted interventions that prevent health related job loss. 
Usual walking speed(WS) is a predictor of health status in adults ≥ 65 years41and 
may also be a useful simple predictor of work status in younger adults with OA. 
The study purpose was to determine whether WS is an independent predictor 
of work status in women with or at risk for osteoarthritis adjusting for covari-
ates. Methods: Participants were 2,634 women (23% African American) age 45-79 
years with baseline WS (Self-selected 20 meters [m]) in the OAI study. Logistic 
regression examined WS as a predictor of work status (working versus not working 
due to health [NWH]) for those walking at slow (< 1.10 meters/second[s]), moderate 
(1.1-1.29 m/s) and normal (> 1.3 m/s) speeds, adjusting for demographics and other 
confounders. Results: Of the 2,634 women (mean age 60.0, Standard Deviation 
[SD] 9.1, years), 57.9% (1,533) were working, 36.0% (952) were not working for other 
reasons and 5.6% (149) were NWH. WS was significantly faster in those working 
compared to those NWH, (mean speed 1.33 m/s vs. 1.08 m/s; p< 0.001). Compared to 
women with normal WS (> 1.3 m/s), those considered slow walkers (WS < 1.10) were 
